203 related articles for article (PubMed ID: 31536761)
1. Long lasting in-situ forming implant loaded with raloxifene HCl: An injectable delivery system for treatment of bone injuries.
Elkasabgy NA; Abdel-Salam FS; Mahmoud AA; Basalious EB; Amer MS; Mostafa AA; Elkheshen SA
Int J Pharm; 2019 Nov; 571():118703. PubMed ID: 31536761
[TBL] [Abstract][Full Text] [Related]
2. In-situ forming chitosan implant-loaded with raloxifene hydrochloride and bioactive glass nanoparticles for treatment of bone injuries: Formulation and biological evaluation in animal model.
Abdel-Salam FS; Elkheshen SA; Mahmoud AA; Basalious EB; Amer MS; Mostafa AA; Elkasabgy NA
Int J Pharm; 2020 Apr; 580():119213. PubMed ID: 32165229
[TBL] [Abstract][Full Text] [Related]
3. Goserelin Acetate Loaded Poloxamer Hydrogel in PLGA Microspheres: Core-Shell Di-Depot Intramuscular Sustained Release Delivery System.
Qi P; Bu R; Zhang H; Yin J; Chen J; Zhang A; Gou J; Yin T; Zhang Y; He H; Wang P; Tang X; Wang Y
Mol Pharm; 2019 Aug; 16(8):3502-3513. PubMed ID: 31251642
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene-/raloxifene-poly(ethylene glycol) conjugate-loaded microspheres: A novel strategy for drug delivery to bone forming cells.
Kavas A; Keskin D; Altunbaş K; Tezcaner A
Int J Pharm; 2016 Aug; 510(1):168-83. PubMed ID: 27343363
[TBL] [Abstract][Full Text] [Related]
5. Silica particles incorporated into PLGA-based in situ-forming implants exploit the dual advantage of sustained release and particulate delivery.
Thalhauser S; Peterhoff D; Wagner R; Breunig M
Eur J Pharm Biopharm; 2020 Nov; 156():1-10. PubMed ID: 32860903
[TBL] [Abstract][Full Text] [Related]
6. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants.
Desai KG; Mallery SR; Schwendeman SP
Eur J Pharm Biopharm; 2008 Sep; 70(1):187-98. PubMed ID: 18472254
[TBL] [Abstract][Full Text] [Related]
7. In situ forming phase-inversion implants for sustained ocular delivery of triamcinolone acetonide.
Sheshala R; Hong GC; Yee WP; Meka VS; Thakur RRS
Drug Deliv Transl Res; 2019 Apr; 9(2):534-542. PubMed ID: 29484530
[TBL] [Abstract][Full Text] [Related]
8. Manufacturing of Dexamethasone-Poly(d,l-Lactide-co-Glycolide) Implants Using Hot-Melt Extrusion: Within- and Between-Batch Product Performance Comparisons.
Kelley RA; Ghaffari A; Wang Y; Choi S; Taylor JR; Hartman RR; Kompella UB
J Ocul Pharmacol Ther; 2020 Jun; 36(5):290-297. PubMed ID: 32330403
[No Abstract] [Full Text] [Related]
9. In Vitro and In Vivo Evaluation of Lidocaine Hydrochloride-loaded Injectable Poly(Lactic-co-glycolic Acid) Implants.
Li Y; Shi X
Curr Drug Deliv; 2018; 15(10):1411-1416. PubMed ID: 30207229
[TBL] [Abstract][Full Text] [Related]
10. Concomitant monitoring of implant formation and drug release of in situ forming poly (lactide-co-glycolide acid) implants in a hydrogel matrix mimicking the subcutis using UV-vis imaging.
Sun Y; Jensen H; Petersen NJ; Larsen SW; Østergaard J
J Pharm Biomed Anal; 2018 Feb; 150():95-106. PubMed ID: 29216591
[TBL] [Abstract][Full Text] [Related]
11. Initial Leuprolide Acetate Release from Poly(d,l-lactide-
Li Z; Mu H; Larsen SW; Jensen H; Østergaard J
Mol Pharm; 2020 Dec; 17(12):4522-4532. PubMed ID: 33164519
[TBL] [Abstract][Full Text] [Related]
12. Construction and performance of exendin-4-loaded chitosan-PLGA microspheres for enhancing implant osseointegration in type 2 diabetic rats.
Shi S; Song S; Liu X; Zhao G; Ding F; Zhao W; Zhang S; Song Y; Ma W
Drug Deliv; 2022 Dec; 29(1):548-560. PubMed ID: 35156499
[TBL] [Abstract][Full Text] [Related]
13. Microencapsulation of amorphous solid dispersions of fenretinide enhances drug solubility and release from PLGA in vitro and in vivo.
Nieto K; Mallery SR; Schwendeman SP
Int J Pharm; 2020 Aug; 586():119475. PubMed ID: 32525080
[TBL] [Abstract][Full Text] [Related]
14. Injectable Sustained-Release Depots of PLGA Microspheres for Insoluble Drugs Prepared by hot-Melt Extrusion.
Guo Y; Yang Y; He L; Sun R; Pu C; Xie B; He H; Zhang Y; Yin T; Wang Y; Tang X
Pharm Res; 2017 Oct; 34(10):2211-2222. PubMed ID: 28741064
[TBL] [Abstract][Full Text] [Related]
15. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.
Desai KG; Mallery SR; Schwendeman SP
Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553
[TBL] [Abstract][Full Text] [Related]
16. Accelerated in vitro release testing method for a long-acting peptide-PLGA formulation.
Goel M; Leung D; Famili A; Chang D; Nayak P; Al-Sayah M
Eur J Pharm Biopharm; 2021 Aug; 165():185-192. PubMed ID: 33992753
[TBL] [Abstract][Full Text] [Related]
17. A smart approach to enable preclinical studies in pharmaceutical industry: PLGA-based extended release formulation platform for subcutaneous applications.
Strack P; Külzer R; Sommer F; Bretschneider T; Merkel OM; Grube A
Drug Dev Ind Pharm; 2020 Apr; 46(4):635-645. PubMed ID: 32163304
[No Abstract] [Full Text] [Related]
18. Formation Mechanism, In vitro and In vivo Evaluation of Dimpled Exenatide Loaded PLGA Microparticles Prepared by Ultra-Fine Particle Processing System.
Zhu C; Peng T; Huang D; Feng D; Wang X; Pan X; Tan W; Wu C
AAPS PharmSciTech; 2019 Jan; 20(2):64. PubMed ID: 30627822
[TBL] [Abstract][Full Text] [Related]
19. Long-Lasting
Bazraee S; Mobedi H; Mashak A; Jamshidi A
Curr Drug Deliv; 2022; 19(1):157-166. PubMed ID: 34139983
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo release of ciprofloxacin from PLGA 50:50 implants.
Ramchandani M; Robinson D
J Control Release; 1998 Jul; 54(2):167-75. PubMed ID: 9724903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
